MIV-711 osteoarthritis phase IIa extension study outcomes show continuing positive effect on joint structure
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces positive top-line joint structure outcomes from the MIV-711 osteoarthritis phase IIa extension study (MIV-711-202). Treatment with MIV-711 over a total 12 months resulted in a continuing treatment effect on joint bone area growth and prevention of cartilage degradation.The MIV-711 phase IIa extension study included patients with moderate knee osteoarthritis who completed 6 months of treatment in the initial phase IIa clinical trial (MIV-711-201). Patients were eligible to participate in the extension study if the pain